Healthcare Industry News: Abraxis BioScience
News Release - April 30, 2008
APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial OfficerSCHAUMBURG, Ill.--(HSMN NewsFeed)--APP Pharmaceuticals, Inc. (Nasdaq:APPX ), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that Thomas H. Silberg has been promoted to president and chief executive officer, succeeding Patrick Soon-Shoing, M.D., who will remain as chairman of the board. The company also announced that Richard J. Tajak has been appointed executive vice president and chief financial officer, succeeding Lisa Gopala. Both Patrick and Lisa served in their roles under a shared services arrangement following the separation of APP and Abraxis BioScience in November 2007. These two appointments are consistent with representations made to the Internal Revenue Service in connection with the receipt of the private letter ruling in the separation.
Mr. Tajak, 55, joined APP in March 2008 as the company’s senior vice president, finance. He has over 20 years of broad and extensive pharmaceutical experience, serving most recently as Sr. Vice President, Finance for the North American operations of Astellas Pharmaceuticals, Inc. Earlier, he held senior management positions at Fujisawa Healthcare/USA and before that at Lyphomed, Inc. Mr. Tajak is a certified public accountant (CPA). He earned a bachelors degree in finance and a masters of business administration degree from the University of Notre Dame.
“Tom is eminently qualified to lead APP and his experience with the company ensures a smooth transition,” said Patrick Soon Shiong. “Rich’s deep and broad expertise in finance, includes corporate and managerial accounting, strategic planning and analysis, treasury, taxation and corporate operations. Both executives have a diverse skill set and bring a wealth of pharmaceutical industry experience to their new roles at APP.”
About APP Pharmaceuticals
APP is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on oncology, anti-infective, anesthetic/analgesic and critical care markets. The company is one of the largest producers of injectables, with more than 100 products in more than 400 dosage formulations. APP, headquartered in Schaumburg, Illinois, has offices in Canada and manufacturing operations in Illinois, New York and Puerto Rico and is traded on the Nasdaq Global Market under the symbol APPX. For more information about APP and the products it provides, please visit www.APPpharma.com.
Source: APP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.